Celsion Corporation to Present at Upcoming Investor Conferences
September 07 2016 - 8:00AM
Optima, a
Global Phase III Study in Newly Diagnosed Primary Liver Cancer
Patients
Celsion Corporation (NASDAQ:CLSN) today announced that Mr.
Michael H. Tardugno, Chairman and CEO and Mr. Jeffrey W. Church,
Sr. Vice President and CFO will be providing updates on its two
promising investigational products being evaluated in Phase III,
II, and I trials at the following upcoming investor conferences,
respectively:
- The Rodman & Renshaw 18th Annual Global Investment
Conference on Monday, September 12, 2016 at 10:50 a.m. Eastern Time
at the Lotte New York Palace Hotel in New York City.
- The 2016 Aegis Capital Growth Conference on Thursday, September
22, 2016 at 9:30 a.m. Pacific Time at the Wynn Las Vegas.
A copy of the presentations can be accessed
under "Financial Events" in the Investors section of the Company's
website at http://investor.celsion.com/events.cfm.
About Celsion
Corporation
Celsion is a fully-integrated oncology
company focused on developing a portfolio of innovative cancer
treatments, including directed chemotherapies, immunotherapies and
RNA- or DNA-based therapies. The Company's lead program is
ThermoDox®, a proprietary heat-activated liposomal encapsulation of
doxorubicin, currently in Phase III development for the treatment
of primary liver cancer and in Phase II development for the
treatment of recurrent chest wall breast cancer. The pipeline
also includes GEN-1, a DNA-based immunotherapy for the localized
treatment of ovarian and brain cancers. Celsion has
two platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies, including TheraPlas™ and TheraSilence™. For more
information on Celsion, visit our
website: http://www.celsion.com (CLSN-FIN).
Celsion wishes to inform readers that
forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data, particularly in small subgroups that are not statistically
significant; FDA and regulatory uncertainties and risks;
the significant expense, time, and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors, regulatory authorities; and
other risks detailed from time to time in
the Celsion's periodic reports and prospectuses filed
with the Securities and Exchange
Commission. Celsion assumes no obligation to update
or supplement forward-looking statements that become untrue because
of subsequent events, new information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Sep 2023 to Sep 2024